Mosaic ImmunoEngineering Files 8-K: Board & Officer Changes
Ticker: CPMV · Form: 8-K · Filed: May 31, 2024 · CIK: 836564
| Field | Detail |
|---|---|
| Company | Mosaic Immunoengineering INC. (CPMV) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1,600, $4 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, officer-changes
TL;DR
Mosaic ImmunoEngineering updated leadership and compensation on 5/31.
AI Summary
Mosaic ImmunoEngineering, Inc. filed an 8-K on May 31, 2024, reporting changes in its board of directors and certain officers, along with updates to compensatory arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate activities and disclosures.
Why It Matters
This filing provides crucial updates on the company's leadership and compensation structures, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance and financial information, not indicating any immediate operational or financial distress.
Key Players & Entities
- Mosaic ImmunoEngineering, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific changes were made to the board of directors or certain officers?
The filing indicates changes in directors and officers, but the specific details of these changes are not provided in the provided text excerpt.
What is the nature of the updates to compensatory arrangements?
The filing mentions updates to compensatory arrangements for certain officers, but the specifics of these arrangements are not detailed in the provided text.
What financial statements and exhibits are included with this filing?
The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When was Mosaic ImmunoEngineering, Inc. incorporated?
Mosaic ImmunoEngineering, Inc. was incorporated in Delaware.
What is the fiscal year end for Mosaic ImmunoEngineering, Inc.?
The fiscal year end for Mosaic ImmunoEngineering, Inc. is December 31st.
Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-05-31 16:30:11
Key Financial Figures
- $1,600 — te"), in exchange for a monthly rate of $1,600. In addition, as previously agreed to b
- $4 million — s completed a capital raise of at least $4 million ("Required Capital Raise"). In exchange
Filing Documents
- mosaic_8k.htm (8-K) — 28KB
- mosaic_ex1001.htm (EX-10.1) — 9KB
- image_002.jpg (GRAPHIC) — 5KB
- 0001683168-24-003923.txt ( ) — 208KB
- cpmv-20240531.xsd (EX-101.SCH) — 3KB
- cpmv-20240531_lab.xml (EX-101.LAB) — 33KB
- cpmv-20240531_pre.xml (EX-101.PRE) — 22KB
- mosaic_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 31, 2024, Mosaic ImmunoEngineering, Inc. a Delaware corporation (the "Company" or "Mosaic") and Mr. Paul Lytle, EVP, Chief Financial Officer of the Company, agreed to amend Mr. Lytle's employment terms from full time status to part time status, not to exceed eight (8) hours per month effective June 1, 2024 ("Effective Date"), in exchange for a monthly rate of $1,600. In addition, as previously agreed to by the parties, all deferred and unpaid compensation ("Deferred Salary") as of the Effective Date will be paid to Mr. Lytle once the Company has completed a capital raise of at least $4 million ("Required Capital Raise"). In exchange for the deferred payment of Mr. Lytle's Deferred Salary, the Company previously agreed to issue Mr. Lytle restricted stock units ("RSU's") equal to 20% of the Deferred Salary amount on the closing date of the Required Capital Raise. The foregoing summary of the terms of Mr. Lytle's employment with the Company does not purport to be complete and is subject to, and qualified in its entirety by, such document attached as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) The following exhibits are being filed herewith: Exhibit No. Description 10 .1 Employment status change letter dated May 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mosaic ImmunoEngineering, Inc. Date: May 31, 2024 By: /s/ Steven King Steven King President and Chief Executive Officer, Director 3